Horizon scanning: Development of tabalumab for rheumatoid arthritis halted
Source: Reuters Health
Area: News
Eli Lilly and Co have halted development of the experimental anti-B-cell activating (BAFF) human monoclonal antibody tabalumab for rheumatoid arthritis following data from a late-stage trial which showed the drug was unlikely to prove effective.
Tabalumab will continue to be tested in late-stage development as a treatment for systemic lupus erythematosus, and in mid-stage development for multiple myeloma.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news
More News: Arthritis | Drugs & Pharmacology | Health | Lupus | Myeloma | PET Scan | Rheumatoid Arthritis | Rheumatology